NEW
YORK, Oct. 13, 2024 /PRNewswire/ -- Report on
how AI is redefining market landscape - The Global Gastrointestinal
Diseases Therapeutics Market size is estimated to grow by
USD 18.5 billion from 2024-2028,
according to Technavio. The market is estimated to grow at a CAGR
of 6.81% during the forecast period. Increasing
incidence of gastrointestinal diseases is driving market
growth, with a trend towards availability of nutritional
therapies. However, high cost of gastrointestinal therapeutics
poses a challenge - Key market players include Abbott
Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies
Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International
GmbH, Boston Scientific Corp., Eisai Co. Ltd., Eli Lilly and Co.,
GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and
Co. Inc., Novartis AG, Olympus Corp., Ovesco Endoscopy AG, Pfizer
Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and UCB SA.
AI-Powered Market Evolution Insights. Our
comprehensive market report ready with the latest trends, growth
opportunities, and strategic analysis- View your snapshot
now
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2017 - 2021
|
Segment
Covered
|
Drug Class
(Anti-inflammatory and immunosuppressors, Acid neutralizers, and
Others), Type (Branded and Generics), and Geography (North America,
Asia, Europe, and Rest of World (ROW))
|
Region
Covered
|
North America, Asia,
Europe, and Rest of World (ROW)
|
Key companies
profiled
|
Abbott Laboratories,
AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer
AG, Biogen Inc., Boehringer Ingelheim International GmbH, Boston
Scientific Corp., Eisai Co. Ltd., Eli Lilly and Co.,
GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and
Co. Inc., Novartis AG, Olympus Corp., Ovesco Endoscopy AG, Pfizer
Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and UCB
SA
|
Key Market Trends Fueling Growth
Gastrointestinal diseases, such as irritable bowel syndrome
(IBS) and celiac disease, require effective therapeutic approaches
to manage symptoms and improve patients' quality of life.
Nutritional therapies, including specialized diets and dietary
supplements, play a significant role in this regard. For instance,
the low-FODMAP diet, which restricts fermentable carbohydrates, can
help manage IBS symptoms. Patients with celiac disease or
non-celiac gluten sensitivity must adhere to a strict gluten-free
diet, with the availability of certified gluten-free products and
clear labeling being essential. Omega-3 fatty acids found in fish
oil supplements have shown potential benefits for inflammatory
bowel disease (IBD) patients. Malnutrition is a common risk for
those with chronic gastrointestinal diseases, necessitating medical
foods and oral nutritional supplements. The availability of these
nutritional therapies complements pharmaceutical treatments,
reducing symptom severity and improving overall quality of life,
thereby driving market growth in the gastrointestinal diseases
therapeutics sector during the forecast period.
The gastrointestinal diseases therapeutics market is
experiencing significant growth due to the rising prevalence of
chronic digestive conditions like Gastroesophageal Reflux Disease
(GERD), Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome
(IBS), and Gastrointestinal cancers. Autoimmune diseases such as
Type 1 diabetes, Multiple Sclerosis, Rheumatoid Arthritis, Lupus,
Crohn's disease, Psoriasis, and Scleroderma also contribute to the
market's expansion. Clinical trials for novel therapies and
targeted drugs, including Inflectra, Remicade, Renflexis, Tysabri,
Ustekinumab, Risankizumab, TNF blockers, and Zeposia, are driving
innovation. Market trends include the use of telemedicine,
biologics, Proton Pump Inhibitors (PPIs), Aminosalicylates,
Antacids, Laxatives, H2 antagonists, and H1 antagonists. Hospital
pharmacies, drug stores, retail pharmacies, and online providers
are key distribution channels for GI drugs. Patent expirations and
the entry of biosimilars are expected to impact market
dynamics.
Insights on how AI is driving innovation,
efficiency, and market growth- Request Sample!
Market Challenges
- Gastrointestinal diseases, such as ulcerative colitis and
Crohn's disease, require ongoing treatment to manage symptoms and
prevent complications, including cancer. Biologics and small
molecules are commonly used therapies. For instance, infliximab
(Remicade, Johnson & Johnson) and vedolizumab (Entyvio, Takeda
Pharmaceutical) are biologic drugs used for chronic
gastrointestinal diseases, with average costs ranging from
USD6,000 to USD8,700. Xeljanz oral tablets (Pfizer) for
ulcerative colitis cost around USD4,900 to USD5,000 for 60 tablets. Physicians often
prescribe steroids and biologics for moderate to severe chronic
gastrointestinal diseases. The average monthly cost of biologics
for IBD is between USD2,500 and
USD5,500. However, rising
out-of-pocket expenses for these therapies and procedures may
hinder the growth of the global gastrointestinal diseases
therapeutics market. The average treatment costs for ulcerative
colitis are USD6,000 to USD12,000, and for Crohn's disease, they are
USD30,000 to USD32,000. These costs primarily consist of
medication, doctor fees, and hospital visits or stays.
- The gastrointestinal diseases therapeutics market faces
significant challenges from various quarters. Biologics, such as
Inflectra, Remicade, Renflexis, Tysabri, Ustekinumab, Risankizumab,
and TNF blockers, dominate the market for chronic digestive
diseases like ulcerative proctitis, IBS, Crohn's disease, and
others. However, patent expirations pose a threat, leading to the
entry of biosimilars. Proton pump inhibitors, H2 antagonists,
aminosalicylates, antacids, and laxatives continue to be popular in
hospital pharmacies, drug stores, retail pharmacies, and online
providers. The injectable segment, including drugs like Humira,
Adalimumab, Certolizumab, Infliximab, and Natalizumab, is growing
rapidly. OTC drugs, such as anti-emetics and laxative preparations,
are also gaining traction in the market. Novel therapies and
targeted drugs offer promising opportunities for innovation.
However, the market is competitive, with various players vying for
market share.
Insights into how AI is reshaping industries and
driving growth- Download a Sample Report
Segment Overview
This gastrointestinal diseases therapeutics market report
extensively covers market segmentation by
- Drug Class
- 1.1 Anti-inflammatory and immunosuppressors
- 1.2 Acid neutralizers
- 1.3 Others
- Type
- Geography
- 3.1 North America
- 3.2 Asia
- 3.3 Europe
- 3.4 Rest of World (ROW)
1.1 Anti-inflammatory and immunosuppressors-
The global gastrointestinal diseases therapeutics market is
experiencing significant growth, particularly in the
anti-inflammatory and immunosuppressors segment. This segment's
expansion is driven by the rising prevalence of inflammatory bowel
diseases (IBDs) such as ulcerative colitis and Crohn's disease.
IBDs are chronic conditions characterized by inflammation in the
digestive tract, leading to moderate to severe abdominal pain.
Anti-inflammatory drugs, including corticosteroids and nonsteroidal
options, are commonly used to alleviate inflammation and pain in
patients with IBDs. Bausch Health Companies Inc. And Merck are
prominent players in the market, offering Colazal (balsalazide
disodium) and various 5-aminosalicylic acid (5-ASA) drugs,
respectively. 5-ASA is a major therapeutic class used to block the
production of inflammatory substances in the initial stages of IBD
treatment. Immunosuppressors, like azathioprine, mercaptopurine,
tofacitinib, and cyclosporine, are another essential class of drugs
that suppress the immune response to inflammation. Pfizer's XELJANZ
(tofacitinib) is an immunosuppressor used for ulcerative colitis
treatment. Biologics, such as TNF inhibitors, anti-integrin,
anti-interleukin-12, and interleukin-23 therapies, are also gaining
popularity for their effectiveness in reducing inflammatory
symptoms among Crohn's disease and ulcerative colitis patients. The
presence of these drugs in the market is expected to fuel the
growth of the anti-inflammatory and immunosuppressors segment and
the gastrointestinal diseases therapeutics market as a whole during
the forecast period.
Download complimentary Sample Report to
gain insights into AI's impact on market dynamics, emerging trends,
and future opportunities- including forecast (2024-2028) and
historic data (2017 - 2021)
Research Analysis
The Gastrointestinal (GI) diseases therapeutics market
encompasses a range of disorders that affect the digestive system,
including gastroesophageal reflux disease (GERD), inflammatory
bowel disease (IBD), irritable bowel syndrome (IBS),
gastrointestinal cancers, autoimmune diseases such as Type 1
diabetes, Multiple sclerosis, Rheumatoid arthritis, Lupus, Crohn's
disease, Psoriasis, and Scleroderma, among others. These chronic
digestive diseases impact millions of people worldwide, leading to
significant morbidity and mortality. Current therapies include GI
drugs, which provide symptomatic relief, and novel therapies such
as targeted drugs that address the underlying causes of these
conditions. The market for GI therapeutics is expected to grow
significantly due to the increasing prevalence of these diseases
and the development of new and innovative treatments.
Market Research Overview
The Gastrointestinal (GI) diseases therapeutics market
encompasses a range of conditions including Gastroesophageal Reflux
Disease (GERD), Inflammatory Bowel Disease (IBD), Irritable Bowel
Syndrome (IBS), Gastrointestinal cancers, Autoimmune diseases such
as Type 1 diabetes, Multiple Sclerosis, Rheumatoid Arthritis,
Lupus, Crohn's disease, Psoriasis, and Scleroderma, among others.
Therapeutic options for these chronic digestive diseases include
Clinical trials, Telemedicine, Biologics, Proton pump inhibitors,
Aminosalicylates, Antacids, Laxatives, H2 antagonists, Peptic ulcer
disease treatments for Gastric ulcer and Duodenal ulcer, and
Hospital pharmacies, Drug stores, Retail pharmacies, and Online
providers. Novel therapies and targeted drugs like Inflectra,
Remicade, Renflexis, Tysabri, Ustekinumab, Risankizumab, TNF
blockers, Zeposia, and others are transforming the treatment
landscape. Patent expirations and the emergence of Biosimilars are
impacting the market dynamics, while Linzess, Humira, Adalimumab,
Certolizumab, Infliximab, Natalizumab, and other key players
dominate the market. The market also includes the Injectable
segment and Over-the-counter (OTC) drugs, Anti-emetics, and
Laxative preparations, available through Online pharmacies.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Drug Class
-
- Anti-inflammatory And Immunosuppressors
- Acid Neutralizers
- Others
- Type
-
- Geography
-
- North America
- Asia
- Europe
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/gastrointestinal-diseases-therapeutics-market-to-grow-by-usd-18-5-billion-from-2024-2028-driven-by-rising-disease-incidence-with-ai-shaping-market-trends--technavio-302273965.html
SOURCE Technavio